REFERENCES

1. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691–706.
2. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9(1):24.
3. Flórez-Tanus Á, Parra D, Zakzuk J, Caraballo L, Alvis-Guzmán N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J [Internet]. 2018 [cited 2018 Dec 1];11(1):26. Available from: https://waojournal.biomedcentral.com/articles/10.1186/s40413-018-0205-4
4. Rodríguez-Martínez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410–8.
5. Erick Bateman. Global Strategy for Asthma Management and Prevention. Glob Iniciative Asthma [Internet]. 2016 [cited 2019 Oct 22];1–147. Available from: www.ginasthma.org
6. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014 Mar;133(3):621–31.
7. Reinhold T, Ostermann J, Thum-Oltmer S, Brüggenjürgen B. Influence of subcutaneous specific immunotherapy on drug costs in children sufferingfrom allergic asthma. Clin Transl Allergy. 2013 Dec 3;3(1):30.
8. Sánchez J, Sánchez A, Cardona R. Consecuencias económicas en la vida real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis. Rev Alerg México. 2016;63(4):323.
9. Demoly P, Makatsori M, Casale TB, Calderon MA. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May;5(3):640–8.
10. Asaria M, Dhami S, van Ree R, Gerth van Wijk R, Muraro A, Roberts G, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy. 2018 Feb;73(2):269–83.
11. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy. 2012 Sep 1;67(9):1087–105.
12. Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, Lynd L, Sadatsafavi M. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. Value Heal. 2019 Sep;22(9):1070–82.
13. Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011 Jan;127(1):57-63.e3.
14. Instituto de Evaluación Tecnológica en Salud-IETS. Manual para la elaboración de evaluaciones económicas en salud [Internet]. Instituto de Evaluación Tecnológica en Salud. Bogotá - Colombia; 2014. Available from: https://www.iets.org.co/Archivos/64/Manual_evaluacion_economica.pdf
15. Bacharier LB. “Step-down” therapy for asthma: Why, when, and how? J Allergy Clin Immunol. 2002 Jun;109(6):916–9.
16. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert T V, Lee TA, et al. Asthma outcomes: Healthcare utilization and costs. J Allergy Clin Immunol. 2012 Mar;129(3):S49–64.
17. Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value? J Allergy Clin Immunol Pract. 2018 Mar;6(2):619–32.
18. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (Update 2019) [Internet]. 2019. p. 1–162. Available from: www.ginasthma.org
19. Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma. Allergy. 2019 May 16;74(5):855–73.
20. Departamento Administrativo Nacional de Estadística (DANE). Vital statistics: birth and deaths forecasting. 2018.
21. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010 Aug 4;(8).
22. Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy Eur J Allergy Clin Immunol. 2017;72(12):1825–48.
23. Sánchez J, Cardona R, Sánchez A. Repercusión de la inmunoterapia con alergenos luego de dos años de suspensión a pacientes con asma. Rev Alerg México. 2016 May 11;63(2):113.
24. Romano G, Y A, López-Delgado N. Análisis de impacto presupuestal de beclometasona, budesonida, ciclesonida, deflazacort, fluticasona (propionato), formoterol, formoterol + budesonida, ipratropio bromuro, metilprednisolona, mometasona, montelukast, omalizumab, prednisolona, salbutamol y. Bogotá, Colombia; 2017.
25. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial. J Allergy Clin Immunol. 2010;126(5):942–9.
26. Lasserson TJ, Cates CJ, Lasserson EH, White J. Fluticasone versus “extrafine” HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006 Apr 19;(2).
27. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford University Press; 2006. 237 p.
28. Dennis R, Caraballo L, Garcia E, Rojas MX, Rondon MA, Perez A et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
29. El-Qutob D, Moreno F, Subtil-Rodriguez A. Specific immunotherapy for rhinitis and asthma with a subcutaneous hypoallergenic high-dose house dust mite extract: Results of a 9-month therapy. Immunotherapy. 2016;8(8):867–76.
30. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8.
31. Ministerio de Salud y Protección social - Colciencias. Guía de práctica clínica Para el diagnóstico, atención integral y seguimiento de niños y niñas con diagnóstico de Asma. Bogotá - Colombia; 2013. 242 p.
32. Sanchez J. Clinical differences between children with asthma and rhinitis in rural and urban areas. Colomb Med. 2018 Jun 1;49(2):169–74.
33. Ministerio de Salud y Protección Social. SISMED - Sistema de Información de Precios de Medicamentos [Internet]. 2019 [cited 2019 Nov 11]. Available from: https://www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx
34. Ministerio de Salud y Protección Social. Acuerdo No. 256 de 2001 - Manual de Tarifas de la Entidad Promotora de Salud del Seguro Social. Bogotá - Colombia; 2001.
35. Szende A, Leidy NK, Ståhl E, Svensson K. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res. 2009 Mar 23;18(2):267–72.
36. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007 Feb 3;16(1):22–7.
37. Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy, Asthma Immunol. 2012;109(4):274–8.
38. Garrison LP. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview. Value Heal. 2016 Jul;19(5):512–5.
39. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real‐world evidence of subcutaneous allergoid immunotherapy in house dust mite‐induced allergic rhinitis and asthma. Allergy. 2020 Mar 12;(January):all.14240.
40. Schmitt J, Wüstenberg E, Küster D, Mücke V, Serup‐Hansen N, Tesch F. The moderating role of allergy immunotherapy in asthma progression: Results of a population‐based cohort study. Allergy [Internet]. 2020 Mar 8 [cited 2020 May 22];75(3):596–602. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14020
41. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy, Asthma Immunol. 2008;101(3):316–24.
42. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Heal. 2012 Sep;15(6):812–20.
43. Dennis RJ, Caraballo L, García E, Rojas MX, Rondon M a, Pérez A, et al. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
44. Zakzuk J, Parra D, Salcedo Mejía F, Alvis-Zakzuk J, Buendia E, Caraballo L, et al. Out-Of-Pocket Health Expenditures In Patients With Uncontrolled Asthma From Colombia. Value Heal. 2016 May;19(3):A16.